Registration Deadline:
Event Contact:
More Information:
Explore other Industry Opportunities:
Grünenthal, a global leader in pain management and related diseases, is seeking therapeutic molecules for oral administration that address both the inflammatory and itch components of inflammatory diseases, such as atopic dermatitis. The company is particularly interested in innovative approaches that address the neuroimmune drivers of chronic itch, via targeting itch-mediating pruriceptors or approaches that modulate the immune-pruriceptor interaction. Grünenthal is open to a range of collaboration opportunities, including licensing assets and research collaborations.
Approaches of interest
- Dermatological diseases including atopic dermatitis, hidradenitis suppurativa, urticaria and prurigo nodularis
- Therapeutic molecules developed for non-dermatological inflammatory diseases targeting relevant pathways for the treatment of itch
- Small molecule assets for oral/systemic administration
Out of scope
- Therapeutics for topical administration
- Drug discovery platforms
- Clinical stage opportunities
Developmental stage of interest: Opportunities that have tangible chemical matter to late preclinical are in scope. Opportunities at lead optimization stage are highest priority.
Summaries generated by AI. Please see attached documentation or email Cameron Sargent, CTTC Licensing Officer, for more information.
Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.